Determinants of concentrations of N(ε)-carboxymethyl-lysine and soluble receptor for advanced glycation end products and their associations with risk of pancreatic cancer.
The soluble receptor for advanced glycation end-products (sRAGE) is shown to mitigate pro-inflammatory effects triggered by ligation of RAGE with N(ε)-carboxymethyl-lysine (CML)-AGE or other ligands. We examined the associations among host, lifestyle, and genetic determinants of CML-AGE or sRAGE and risk of pancreatic cancer in the prospective ATBC Study. We obtained baseline exposure information, data on serological and genetic biomarkers from 141 patients with pancreatic cancer and 141 subcohort controls. Stepwise linear and logistic regression models were used for data analysis. Multiple linear regression analyses showed that CML-AGE concentrations were independently inversely correlated with the minor allele of rs640742 of DDOST, physical activity, alcohol consumption, diastolic blood pressure (BP), and positively correlated with heart rate, serum sRAGE and HDL concentrations (P < 0.05). sRAGE concentrations were independently inversely correlated with the 82Ser allele of rs2070600 of RAGE, age, body mass index, heart rate, and serum HDL; and positively correlated with serum CML-AGE, sucrose consumption, and diastolic BP (P < 0.05). The minor allele of rs1035786 of RAGE was associated with reduced risk of pancreatic cancer (any T compared with CC: multivariate OR = 0.61, 95% CI: 0.38-0.98). We identified host metabolic profile, lifestyle and genetic factors that explained approximately 50% of variability of CML-AGE or sRAGE in Finnish men smokers. The association between RAGE SNPs and pancreatic cancer risk warrants further investigation.
Department of Medicine, Baylor College of Medicine Houston, TX, USA ; Section of Health Services Research (IQuESt), Michael. E DeBakey VA Medical Center Houston, TX, USA.
Zhigang
Z
Duan
Division of Health Services Research, University of Kansas Medical Center Kansas City, KS, USA.
Guoqing
G
Chen
Department of Medicine, Baylor College of Medicine Houston, TX, USA ; Section of Health Services Research (IQuESt), Michael. E DeBakey VA Medical Center Houston, TX, USA.
Liang
L
Chen
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health Bethesda, MD, USA.
Rachael
R
Stolzenberg-Solomon
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health Bethesda, MD, USA.
Stephanie J
SJ
Weinstein
Department of Chronic Disease Prevention, National Institute for Health and Welfare Helsinki, Finland.
Satu
S
Mannisto
Department of Medicine, Baylor College of Medicine Houston, TX, USA ; Section of Health Services Research (IQuESt), Michael. E DeBakey VA Medical Center Houston, TX, USA ; Texas Medical Center Digestive Disease Center Houston, TX, USA ; Dan L. Duncan Cancer Center at Baylor College of Medicine Houston, TX, USA ; Center for Translational Research on Inflammatory Diseases (CTRID), Michael E. DeBakey Veterans Affairs Medical Center Houston, TX, USA.
Donna L
DL
White
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health Bethesda, MD, USA.
Demetrius
D
Albanes
Department of Medicine, Baylor College of Medicine Houston, TX, USA ; Section of Health Services Research (IQuESt), Michael. E DeBakey VA Medical Center Houston, TX, USA ; Texas Medical Center Digestive Disease Center Houston, TX, USA ; Dan L. Duncan Cancer Center at Baylor College of Medicine Houston, TX, USA ; Center for Translational Research on Inflammatory Diseases (CTRID), Michael E. DeBakey Veterans Affairs Medical Center Houston, TX, USA.
Li
L
Jiao
Advanced glycation end-products; inflammation; metabolic syndrome; pancreatic cancer; sRAGE; single nucleotide polymorphism